Profile
Marie Kosco-Vilbois served as the Chief Scientific Officer at AC Immune SA from 2019 to 2024.
Prior to that, she was the Chief Scientific Officer at NovImmune SA from 2005 to 2019.
She also held positions at Serono Pharmaceutical Research Institute and Glaxo-Welcomes' Research Institute.
Before her career in industry, she was a Scientific Member at Basel Institute for Immunology.
Kosco-Vilbois received her undergraduate degree from Rutgers State University of New Jersey and her doctorate from Medical College of Virginia in 1985.
Former positions of Marie Kosco-Vilbois
| Companies | Position | End |
|---|---|---|
| AC IMMUNE SA | Chief Tech/Sci/R&D Officer | 01/01/2024 |
| NOVIMMUNE SA | Chief Tech/Sci/R&D Officer | 09/01/2019 |
| Serono Pharmaceutical Research Institute | Corporate Officer/Principal | 01/01/2001 |
| Basel Institute for Immunology | Corporate Officer/Principal | - |
| Glaxo-Welcomes' Research Institute | Corporate Officer/Principal | - |
Training of Marie Kosco-Vilbois
| Rutgers State University of New Jersey | Undergraduate Degree |
| Medical College of Virginia | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Private companies | 3 |
|---|---|
Novimmune SA
 Novimmune SA Medical/Nursing ServicesHealth Services Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland. | Health Services |
| Serono Pharmaceutical Research Institute | |
| Glaxo-Welcomes' Research Institute |
- Stock Market
- Insiders
- Marie Kosco-Vilbois
